Charles River Labs beats Q2 2026 estimates as biotech demand rebounds
As seen on the 24/7 Wall St. homepage on August 5, 2026.
Biotech R&D budgets are unfreezing: the Discovery and Safety Assessment segment booked its highest net book-to-bill in nearly four years, with demand improving across both large pharma and small-cap biotech clients. That was enough to lift full-year non-GAAP EPS guidance to $11.15 to $11.45 and push organic growth guidance back to positive territory, with management's read on the order book due on today's 9:00 AM ET call.
Continue ReadingShow less
Charles River Laboratories reported Q2 2026 non-GAAP EPS of $3.02, clearing the consensus estimate of $2.73 by roughly 11%. Revenue came in at just over $1 billion, beating expectations of $977 million by about 2.75%. The results mark a meaningful step up from Q1 2026's $2.06 EPS print and suggest the company is regaining momentum after several quarters of compressed results.
The standout detail from the quarter was the Discovery and Safety Assessment segment, which posted its highest net book-to-bill ratio in nearly four years. Management noted demand improving across both large pharma and small-cap biotech clients — a signal that R&D budgets that had been on hold are beginning to open back up. That improving order book gave the company enough confidence to lift its full-year non-GAAP EPS guidance to a range of $11.15 to $11.45 and push organic growth guidance back into positive territory.
Investors looking for more color on the order book and the sustainability of that demand recovery had a management call at 9:00 AM ET on August 5 to watch. Charles River has beaten EPS estimates in each of the past eight quarters, though the magnitude of those beats has varied widely, ranging from a slim outperformance in Q4 2025 to the larger surprise delivered this quarter.
Mentioned: CRL